TriSalus Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Cash & Equivalents	11.78	9.41	30.3	1.33
Cash & Cash Equivalents	11.78	9.41	30.3	1.33
Cash Growth	25.10%	-68.93%	2169.74%	-
Receivables	3.55	1.56	1.36	0
Inventory	2.55	1.47	1.29	0
Other Current Assets	2.99	4.77	2.18	0.67
Total Current Assets	20.86	17.21	35.13	2.01
Property, Plant & Equipment	3.27	3.61	1.8	0
Long-Term Investments	0	0	0	250
Goodwill and Intangibles	1.13	0.8	0.79	0
Other Long-Term Assets	0.47	0.37	0.12	0
Total Long-Term Assets	4.86	4.78	2.71	250
Total Assets	25.73	22	37.84	252.01
Accounts Payable	3.39	4.95	1.3	0
Current Debt	0.35	0.37	0	-
Other Current Liabilities	10.95	27.04	5.07	-
Total Current Liabilities	14.69	32.36	6.37	-
Long-Term Debt	1.24	1.59	0	-
Other Long-Term Liabilities	35.73	0.37	0.56	-
Total Long-Term Liabilities	36.98	1.96	0.56	-
Total Liabilities	51.66	34.32	6.93	23.5
Total Debt	1.6	1.96	0	0
Debt Growth	-18.75%	-	-	-
Retained Earnings	-248.38	-186.36	-136.34	-21.49
Shareholders' Equity	-25.94	-176.33	-129.6	-21.48
Net Cash / Debt	10.18	7.45	30.3	1.33
Net Cash / Debt Growth	36.65%	-75.41%	2169.74%	-
Net Cash Per Share	1.08	24.07	138.30	0.16
Working Capital	6.18	-15.14	28.76	-
Book Value Per Share	-2.76	-569.52	-591.53	-2.57

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).